TrialAnnals of the rheumatic diseases2022

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.

Edward M Vital et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.